CEO: Maarten de Chateau
CEO: Maarten de Chateau
CEO: Lars Öhman
About the Janssen Pharmaceutical Companies
At the Janssen Pharmaceutical Companies of Johnson & Johnson, we are working to create a world without disease. Transforming lives by finding new and better ways to prevent, intercept, treat and cure disease inspires us. We bring together the best minds and pursue the most promising science. We are Janssen. We collaborate with the world for the health of everyone in it. Learn more at www.janssen.com. Follow us on www.twitter.com/janssenEMEA for our latest news.
Description: CellProtect Nordic Pharmaceuticals AB, CPNP, is developing new therapies based on mesenchymal and Natural killer (NK) cells to treat severe diseases. CellProtect, ex vivo expanded and activated Natural killer (NK) cells is the lead investigational drug candidate and is being evaluated as adjunct treatment to autolog stem cell transplantation in patients with Multiple Myeloma. A First in Human phase I/II clinical study, is conducted at the Hematology Center at Karolinska University Hospital Huddinge. The company owns assets related to the manufacturing technology including patent applications. A patent has been issued in China and U.S.
CellProtect Nordic Pharmaceuticals AB was founded 2011 and is supported by the 17 shareholders holding expertise in the field. The company is the commercial partner in a cell therapy consortium financed by VINNOVA.
General Manager: Patric Stenberg
Cadila Pharmaceuticals Sweden AB is a wholly-owned subsidiary of Cadila Pharmaceuticals Limited, India.
Over the last six decades, the company has been developing, manufacturing and selling pharmaceutical products in over eighty-five countries around the World.
Our product basket includes branded and generic formulations covering more than 45 therapeutic segments, biotechnology products, plant tissue culture and more than 38 APIs and intermediates. In the services realm, our offering includes Pre-Clinical and Clinical Research as well as Contract Manufacturing.
We have scientific collaborations with leading Swedish companies for preventing in-patient infections and development of novel treatment for specific and acute infections, for developing Antibiotic Resistant Breakers and innovative treatment in inflammation and pain management.
The Swedish office has been set up to ensure success of ongoing and future collaborations between Swedish companies and institutions, and our Indian organization. We encourage regional researchers and companies to get in touch with us to discuss potential collaborations or our service offerings.
Description: iCellate has developed an instrument for sensitive, specific and universal cancer cell isolation that meets physicians’, and research scientists’ previously unmet needs. It can capture the heterogeneous, plastic and extremely rare circulating tumor cells against a background of normal blood cells. This instrument therefore lets the scientists capture and analyse the spreading cancer cells, in flagranti, as they spread. The instrument also provides opportunities for new kinds of cancer tests such as early detection of spreading cancer using a standard blood test or monitoring tumor cell concentration during cancer treatment.
CEO: Thomas Olin
Description: Kancera develops new therapeutics, starting with a biological discovery and ending with an effective and safe drug candidate ready for clinical trials. Kancera focuses on the development of drug candidates with potential to combat therapy resistance and relapse in cancer. In addition, Kancera develops humanized cancer models for the evaluation of drug candidates and biomarkers. The wholly owned subsidiary iNovacia provides analytical development, screening, medicinal chemistry and ADME resources for the development of chemical probes and drug candidates to both academia and life science companies. We have partners and customers in Europe, the US and in South America.
CEO: Ulrika Wennberg
CEO: Christian S. Schade
Aprea AB is a Swedish biotech company focusing on discovery and development of novel anticancer compounds targeting the tumor suppressor protein p53. Aberrations in p53 are common in many various cancer forms and are associated with increased resistance to standard chemotherapy and thus poor prognosis. Aprea is a Karolinska Development AB (publ) portfolio company. The other main owners are Industrifonden, Östersjöstiftelsen, Praktikerinvest and KD Co-Investment Fund KB.
APR-246 has been developed based on results from researcher at the Karolinska Institutet. The researchers have discovered that the substance is more efficacious in cancer cells than normal cells, which indicates that it could produce significantly fewer side effects than conventional cancer treatments. By reactivating the tumor suppressor protein p53 the compound induces the cellular suicide program that eliminates the cancer cells. This has been shown in both in vitro laboratory studies and animal in vivo studies with good results. A unique characteristic of the substance is that it can activate p53 even when the gene is mutated. Cancers with mutated p53 are often more resistant to conventional treatment.